# Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

> **NCT05148871** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vaxine Pty Ltd** · enrollment: 200 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Spikogen/Covax-19

## Key facts

- **NCT ID:** NCT05148871
- **Lead sponsor:** Vaxine Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2023-02-23
- **Final completion:** 2024-10-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05148871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05148871, "Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05148871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*